Suscribirse

Airway and parenchymal transcriptomics in a novel model of asthma and COPD overlap - 04/10/22

Doi : 10.1016/j.jaci.2022.04.032 
Xiaofan Tu, BMedSci(Hons) a, , Richard Y. Kim, PhD a, b, , Alexandra C. Brown, PhD a, Emma de Jong, PhD c, Bernadette Jones-Freeman, PhD a, d, Md Khadem Ali, PhD a, Henry M. Gomez, PhD a, Kurtis F. Budden, PhD a, Malcolm R. Starkey, PhD a, d, Guy J.M. Cameron, PhD a, Svenja Loering, MSc a, Duc H. Nguyen, PhD a, Prema Mono Nair, PhD a, Tatt Jhong Haw, PhD a, Charlotte A. Alemao, MSc a, Alen Faiz, PhD b, Hock L. Tay, PhD a, Peter A.B. Wark, MD, PhD a, Darryl A. Knight, PhD a, e, Paul S. Foster, DSc a, Anthony Bosco, PhD c, Jay C. Horvat, PhD a, Philip M. Hansbro, PhD a, f, , , Chantal Donovan, PhD a, b, ,
a Priority Centre for Healthy Lungs, Hunter Medical Research Institute and The University of Newcastle, Newcastle, Australia 
b Faculty of Science, School of Life Sciences, University of Technology Sydney, Sydney, Australia 
c Telethon Kids Institute, Centre for Health Research, The University of Western Australia, Nedlands, Australia 
d Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, Australia 
e Providence Health Care Research Institute, Vancouver, British Columbia, Canada 
f Centre for Inflammation, Faculty of Science, School of Life Sciences, Centenary Institute and University of Technology Sydney, Sydney, Australia 

Corresponding author: Philip Hansbro, PhD, Centenary Institute, Building 93 RPA Hospital, Missenden Road, Camperdown, New South Wales 2050, Australia.Centenary InstituteBuilding 93 RPA HospitalMissenden RoadCamperdownNew South Wales2050Australia∗∗Chantal Donovan, PhD, University of Technology Sydney, PO Box 123, Broadway, Ultimo, New South Wales 2007, Australia.University of Technology SydneyPO Box 123BroadwayUltimoNew South Wales2007Australia

Abstract

Background

Asthma and chronic obstructive pulmonary disease (COPD) are common chronic respiratory diseases, and some patients have overlapping disease features, termed asthma-COPD overlap (ACO). Patients characterized with ACO have increased disease severity; however, the mechanisms driving this have not been widely studied.

Objectives

This study sought to characterize the phenotypic and transcriptomic features of experimental ACO in mice induced by chronic house dust mite antigen and cigarette smoke exposure.

Methods

Female BALB/c mice were chronically exposed to house dust mite antigen for 11 weeks to induce experimental asthma, cigarette smoke for 8 weeks to induce experimental COPD, or both concurrently to induce experimental ACO. Lung inflammation, structural changes, and lung function were assessed. RNA-sequencing was performed on separated airway and parenchyma lung tissues to assess transcriptional changes. Validation of a novel upstream driver SPI1 in experimental ACO was assessed using the pharmacological SPI1 inhibitor, DB2313.

Results

Experimental ACO recapitulated features of both asthma and COPD, with mixed pulmonary eosinophilic/neutrophilic inflammation, small airway collagen deposition, and increased airway hyperresponsiveness. Transcriptomic analysis identified common and distinct dysregulated gene clusters in airway and parenchyma samples in experimental asthma, COPD, and ACO. Upstream driver analysis revealed increased expression of the transcription factor Spi1. Pharmacological inhibition of SPI1 using DB2313, reduced airway remodeling and airway hyperresponsiveness in experimental ACO.

Conclusions

A new experimental model of ACO featuring chronic dual exposures to house dust mite and cigarette smoke mimics key disease features observed in patients with ACO and revealed novel disease mechanisms, including upregulation of SPI1, that are amenable to therapy.

El texto completo de este artículo está disponible en PDF.

Key words : Asthma COPD overlap, SPI1, transcriptomics, house dust mite, cigarette smoke

Abbreviations used : ACO, AHR, AIR, BALF, ChEA3, COPD, CS, DEG, DEX, FLAME, GO, HDM, log2FC, Padj, RNA-seq, WGCNA


Esquema


 Supported by an Australian Government Research Training Program Scholarship to X.T., a Lung Foundation Australia Boehringer Ingelheim Fellowship to R.Y.K., a National Health and Medical Research Council Investigator Grant (1179187) and UTS to P.M.H., and National Health and Medical Research Council Early Career Fellowship (1120152) and grant (1138402) to C.D.
 Disclosure of potential conflict of interest: A. Bosco founded INSiGENe Pty Ltd, co-founded Respiradigm Pty Ltd, and receives consulting fees from Merck Sharp & Dohme outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.


© 2022  American Academy of Allergy, Asthma & Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 150 - N° 4

P. 817 - octobre 2022 Regresar al número
Artículo precedente Artículo precedente
  • Nasopharyngeal airway dual-transcriptome of infants with severe bronchiolitis and risk of childhood asthma: A multicenter prospective study
  • Zhaozhong Zhu, Carlos A. Camargo, Yoshihiko Raita, Robert J. Freishtat, Michimasa Fujiogi, Andrea Hahn, Jonathan M. Mansbach, Jonathan M. Spergel, Marcos Pérez-Losada, Kohei Hasegawa
| Artículo siguiente Artículo siguiente
  • Feno differentiates epithelial gene expression clusters: Exploratory analysis from the MESOS randomized controlled trial
  • Sarah Diver, Sriram Sridhar, Latifa C. Khalfaoui, Richard J. Russell, Claire Emson, Janet M. Griffiths, Melissa de los Reyes, Da Yin, Gene Colice, Christopher E. Brightling

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.